A cross‑sectional analysis found substantial variation across state Medicaid programs in coverage and prior‑authorization requirements for antiobesity GLP‑1 receptor agonists. The paper by Klebanoff, Chetty, and Doshi documents different formulary practices and administrative hurdles that affect patient access to GLP‑1 medicines. The study highlights how coverage disparities could shape prescribing patterns and market uptake. GLP‑1 receptor agonists act on incretin pathways to lower glucose and reduce appetite, a mechanism central to both diabetes and obesity indications.